Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amarin Builds Sales Infrastructure For EU Vazkepa Launch

CHMP Positive Opinion At January Meeting

Executive Summary

With an approval nod from the EMA’s scientific committee for its fish oil product Vazkepa, launch plans for the EU for this “multi-billion dollar” opportunity are on track, says Amarin CEO.

You may also be interested in...



Stada-Mabxience Bevacizumab Is Latest To Receive EU Nod

Stada and Mabxience have received an endorsement from the EMA for their partnered bevacizumab biosimilar rival to Avastin. Meanwhile, Riemser’s thiotepa generic and two Teva inhalers have also received positive opinions from the CHMP.

Never Give Up: Amarin Will Appeal Latest Vascepa Patent Loss

A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.

Quick Listen: The Story Behind The Pharmaprojects’ Pharma R&D Annual Review 2021

In this one-off podcast, hear in the inside story of how the Pharmaprojects’ Pharma R&D Annual Review 2021 is put together, its history and the trends it has revealed in R&D over the years.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel